Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) generates frequent news as an ophthalmology-focused biopharmaceutical company advancing late-stage retinal programs and a commercial eye-care product. Its press releases highlight progress across the AXPAXLI (OTX-TKI) clinical programs in wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), as well as updates related to DEXTENZA, financings, and corporate events.
News coverage for OCUL commonly includes clinical milestones such as target randomization in the SOL-R Phase 3 wet AMD trial, completion of randomization in SOL-1, and the initiation or advancement of the HELIOS Phase 3 registrational program in NPDR. The company also issues announcements about regulatory strategy, including Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration for SOL-1 and HELIOS-2 and plans to leverage the 505(b)(2) pathway for AXPAXLI in wet AMD.
Investors following OCUL news will see regular business and capital markets updates, such as underwritten equity offerings, cash runway disclosures, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). The company also reports quarterly financial results and business highlights, describing clinical execution, trial timelines, and planned extension studies like SOL-X for long-term evaluation of AXPAXLI in wet AMD.
In addition, Ocular Therapeutix announces participation in scientific and investor conferences, where it presents data from earlier-stage trials (for example, HELIOS Phase 1 results in NPDR) and discusses its strategy to "redefine the retina experience." For a consolidated view of these developments, the OCUL news page on Stock Titan brings together clinical, regulatory, financial, and corporate communications so readers can track how trial outcomes, regulatory interactions, and financing activities may shape the company’s ophthalmic pipeline and commercial portfolio over time.
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple investor conferences in March 2026, including TD Cowen (March 2), Jefferies Biotech on the Beach (March 10), Citizens Life Sciences and Barclays (March 11) and RBC Ophthalmology (March 24).
Pravin U. Dugel, MD, Executive Chairman, President and CEO, will deliver several fireside chats. Live webcasts of TD Cowen, Citizens and RBC presentations will be available on the Investor Relations Events and Presentations page, with replays archived for at least 30 days.
Ocular Therapeutix (NASDAQ: OCUL) will present detailed SOL-1 Phase 3 superiority trial data for AXPAXLI (OTX-TKI) in wet AMD at the 49th Macula Society Annual Meeting on Feb 27, 2026, with presentations starting at 1:00 PM PT (4:00 PM ET).
The company will furnish symposium slides on Form 8-K at 4:00 PM ET on Feb 27 and host an investor webcast to discuss the data on Mar 2, 2026 at 7:30 AM ET; slides and a replay will be available on the company website.
Ocular Therapeutix (NASDAQ: OCUL) reported positive topline SOL-1 Phase 3 results for AXPAXLI in wet AMD on February 17, 2026. The trial met its FDA-aligned superiority primary endpoint at Week 36 (74.1% vs 55.8%, risk difference 17.5%, p=0.0006) and a durable Week 52 outcome (65.9% vs 44.2%, risk difference 21.1%, p<0.0001).
AXPAXLI showed higher rescue-free rates, superior Week 36 CSFT control (55.9% vs 37.8%, nominal p=0.0013), no treatment-related ocular SAEs, and plans to pursue an NDA pending FDA discussions. SOL-R non-inferiority trial continues with topline expected 1Q 2027.
Ocular Therapeutix (NASDAQ: OCUL) will host a webcast on Tuesday, February 17, 2026 at 8:00 AM ET to review topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration.
Detailed SOL-1 data will be presented at the 49th Macula Society Annual Meeting from February 25–28, 2026. The live webcast and archived replay (available for at least 30 days) can be accessed via the company's Investor Relations Events and Presentations page.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to five newly hired non-executive employees effective February 2, 2026. The grants include non‑statutory stock options for an aggregate of 13,850 shares (exercise price $9.15) and restricted stock units for 4,600 shares.
Options have a ten‑year term and four‑year vesting (25% after one year, then monthly). RSUs vest over three years in equal annual installments, subject to continued service and award agreement terms under the 2019 Inducement Stock Incentive Plan.
Ocular Therapeutix (NASDAQ: OCUL) reported Q4 and full‑year 2025 results and business highlights on Feb 5, 2026. Key items: SOL‑1 Week 52 topline data expected at the 49th Macula Society meeting Feb 25–28, 2026; plan to file an NDA for AXPAXLI pending positive SOL‑1 results; SOL‑R randomized 631 subjects; cash of $737.1M supporting runway into 2028.
2025 revenue declined to $52.0M and net loss was $265.9M; R&D spending rose sharply to $197.1M.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity to new Global Chief Commercial Officer David W. Robinson, effective January 21, 2026, under the 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards consist of a non‑statutory stock option to purchase 416,000 shares (exercise price $11.42, ten‑year term, vests over four years with 25% after one year) and restricted stock units representing 136,000 shares (vests over three years, first installment on January 21, 2027). Awards are subject to the award agreements and plan terms.
Ocular Therapeutix (NASDAQ: OCUL) appointed David W. Robinson as Global Chief Commercial Officer effective Jan 21, 2026. Robinson brings deep retina launch experience, including a lead role on the EYLEA launch and recent service as Chief Marketing Officer, Global Ophthalmology at Merck. He will report to Pravin U. Dugel and join the Executive Leadership Team, leading the global commercial franchise and launch readiness for AXPAXLI (OTX-TKI) for wet AMD and NPDR, if approved. Steve Meyers will continue as Chief Commercial Officer and collaborate on AXPAXLI while leading DEXTENZA marketing.
Ocular Therapeutix (NASDAQ: OCUL) intends to submit an NDA for AXPAXLI in wet AMD shortly after positive year‑one SOL‑1 topline data, which are on track for 1Q 2026. The company plans to leverage the 505(b)(2) pathway and cites an existing SPA and a superiority trial design versus aflibercept to support an accelerated review. Ocular says AXPAXLI could be the first TKI commercialized for wet AMD with potential durability up to 12 months. The company will continue SOL‑1 into year two and run SOL‑R and SOL‑X to provide additional data for clinicians and payors.
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eight newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards, effective December 1, 2025, consist of non-statutory stock options to purchase an aggregate of 51,600 shares and restricted stock units representing an aggregate of 17,066 shares. The stock options carry a $11.71 exercise price (closing Nasdaq price on the effective date), have a 10-year term, and vest over four years (25% after one year, then monthly over three years). The restricted stock units vest over three years in equal annual installments, with the first vesting on December 1, 2026. Awards are subject to the award agreements and the inducement plan terms.